Aspirin-induced asthma

Description

In some asthma individuals, acetylsalicylic acid (aspirin®™) and other nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase 1 (COX-1) exacerbate the condition. This distinct clinical syndrome, called aspirin-induced asthma (AIA), is characterised by an eosinophilic rhinosinusitis, nasal polyposis, aspirin hypersensitivity, and asthma.

Index terms

Aspirin-induced asthma
Asthma with aspirin triad including nonsteroidal anti-inflammatory activity and nasal polyps
acetylsalicylic acid-induced asthma

Exclusions from above levels

CA22 – chronic obstructive asthma
CA22.1 – chronic asthmatic (obstructive) bronchitis
CA60.1 – miner’s asthma

Show allHide

CA70 – wood asthma
MD11.C – Wheezing
01 – Certain infectious or parasitic diseases
05 – Endocrine, nutritional or metabolic diseases
18 – Complications of pregnancy, childbirth and the puerperium
19 – Certain conditions originating in the perinatal period
20 – Congenital malformations, deformations and chromosomal abnormalities
22 – Injury, poisoning or certain other consequences of external causes

Sibling codes

CA23.21 – Exercise-induced bronchospasm
CA23.22 – Cough variant asthma

Foundation entity

Aspirin-induced asthma – http://id.who.int/icd/entity/1030818265

Allowed postcoordination axes

Part of: CA23.2: Other specified forms of asthma or bronchospasm › CA23: Asthma › 12: Diseases of the respiratory system